The Gonorrhea Turnaround: Five New Weapons

On December 12, 2025, the FDA did something it had not done in over thirty years. It approved two new classes of antibiotics for gonorrhea — on the same day. Zoliflodacin (Nuzolvence) and gepotidacin (Blujepa) represent the first genuinely new mechanisms of action against Neisseria gonorrhoeae since the fluoroquinolones of the early 1990s. For a pathogen that has defeated every antibiotic ever thrown at it — sulfonamides, penicillin, tetracycline, ciprofloxacin, azithromycin — this was a rare and genuine victory. But the story of gonorrhea and antibiotics is not a story of victories. It is a story of arms races. And the arms race is already underway. Eighty-Two Million Reasons to Worry Gonorrhea infects an estimated 82.4 million people every year — the second most common bacterial sexually transmitted infection on Earth. Left untreated, it causes pelvic inflammatory disease, infertility, and ectopic pregnancy. It facilitates HIV transmission. In newborns, it causes blindness. And it is winning. The WHO's Enhanced Gonococcal Antimicrobial Surveillance Programme (EGASP) paints a stark picture. From 2022 to 2024, resistance to ceftriaxone — the last remaining first-line treatment — rose from 0.8% to 5% globally. Cefixime resistance climbed from 1.7% to 11%. Azithromycin resistance went from 0.5% to 4%. And ciprofloxacin? Already 95% resistant. A sixfold increase in resistance to the last-line drugs in just two years. The hotspots are concentrated in Southeast Asia. Vietnam reports 24-27% ceftriaxone resistance. Cambodia is similarly affected. China's five most affected provinces exceed 10%. But the problem is globalizing. In 2024, twelve countries across five WHO regions were reporting data — up from just four in 2022. Gonorrhea was on a trajectory to become one of the first diseases to become functionally untreatable. Then came December 12. Two New Classes, One Historic Day Zoliflodacin is a spiropyrimidinetrione — a first-in-class compound that targets the GyrB subunit of bacterial DNA gyrase. Unlike fluoroquinolones, which target GyrA and ParC, zoliflodacin binds a completely different site on the gyrase complex. It is given as a single oral dose. In phase 3 trials — the largest ever conducted for a gonorrhea antibiotic, with 958 patients across five countries — it achieved a 90.9% microbiological cure rate for urogenital infections. Gepotidacin is a triazaacenaphthylene — another first-in-class, targeting both GyrA and ParC but through a novel binding mechanism distinct from fluoroquinolones. Developed by GSK, it was first approved for urinary tract infections in March 2025, then for gonorrhea on December 11, 2025. Its phase 3 trial showed 92.6% cure for urogenital gonorrhea — actually outperforming the ceftriaxone comparator arm (91.0%). Two new drugs. Two new mechanisms. Both oral. Both single-course. Both effective against strains that resist everything in the current arsenal. But the real innovation was not just the molecules. It was how they got here. The GARDP Model: Access by Design Zoliflodacin's development story breaks the mold of antibiotic R&D. It was developed through a partnership between GARDP (the Global Antibiotic Research and Development Partnership, a nonprofit) and Innoviva Specialty Therapeutics. Under their agreement, Innoviva holds commercial rights in the US, EU, UK, and other high-income markets. GARDP holds the license for more than 160 countries — every low-income country and most middle-income ones. This is access built into the drug's architecture from day one, not bolted on as an afterthought. GARDP submitted zoliflodacin for priority review in Thailand in November 2025, with South Africa planned for early 2026. These were not arbitrary choices — both countries hosted phase 3 trial sites. Thailand could have zoliflodacin available within months of the US launch. GARDP is already defining a roadmap for twenty wave 2 countries. The US commercial launch is planned for the second half of 2026. But in the places where gonorrhea is most common — Southeast Asia, sub-Saharan Africa, Latin America — GARDP's nonprofit pathway may actually deliver the drug faster than the commercial one. As the 2026 AMR Benchmark report noted, only Innoviva (for zoliflodacin) and Otsuka among small and medium pharmaceutical companies have detailed plans addressing availability, affordability, and supply in low- and middle-income countries. The Pipeline Behind the Headlines Zoliflodacin and gepotidacin are not the end of the story. They are the beginning of what could be an unprecedented wave of anti-gonococcal innovation — if the pipeline holds. Debio 1453 (Debiopharm) targets FabI, an enzyme essential for fatty acid synthesis in N. gonorrhoeae. Published in Nature Communications in 2025, preclinical data showed sub-nanomolar potency, activity against all multidrug-resistant phenotypes tested, and low propensity for resistance selection. It also shows activity against Chlamydia trachomatis. Phase 1 began in August 2025, with CARB-X funding exceeding $20 million. In January 2026, GARDP and Debiopharm partnered — giving GARDP manufacturing and commercialization rights across 160+ countries. NQNO (2-nonyl-4-quinolone N-oxide) takes a radically different approach. Described by Hauck and Böttcher in Nature Microbiology (2025), this compound disrupts the gonococcal electron transport chain, depleting ATP and generating oxidative stress. This triggers degradation of the Epsilon1 antitoxin, releasing the endogenous Zeta1 toxin — essentially activating the bacterium's own suicide program. Because the toxin-antitoxin system is unique to gonococci, NQNO spares commensal Neisseria, vaginal lactobacilli, and human cells entirely. TXA 15054 (TAXIS Pharmaceuticals) inhibits dihydrofolate reductase (DHFR) — but through a binding mode completely different from trimethoprim, which has zero activity against gonorrhea. Five distinct mechanisms of action against a single pathogen. There has never been a moment like this in gonococcal drug development. The Shadow: Resistance Is Already Evolving N. gonorrhoeae has defeated every antibiotic ever used against it. The gyrB D429N mutation — known to confer zoliflodacin resistance — also confers cross-resistance to gepotidacin in some strain backgrounds. WHO EGASP surveillance data from 2021-2024 found two isolates from Cambodia already carrying gyrB D429N. The drugs have not even launched, and the mutations are already circulating in the wild. The doxyPEP paradox: from 2018 to 2024, tetM-carrying N. gonorrhoeae expanded from less than 10% to over 30% of US isolates. Two of the four major tetM lineages also carry penA variants that increase ceftriaxone resistance. The prescribing landscape shapes gonococcal ecology. Helekal and Grad at Harvard quantified this for the first time using a hierarchical Bayesian phylodynamic model on 20 years of surveillance data. What Must Happen Now The gonorrhea turnaround is real, but fragile. Five new mechanisms of action. A nonprofit access model being built from the ground up. Expanding global surveillance. For the first time in decades, the therapeutic pipeline is ahead of the pathogen. But staying ahead requires discipline: stewardship from day one, integrated genomic surveillance, combination thinking, and equitable access.